Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114547 | 0.86 | KCNN4 (0.46) | CNR1CNR2HSD17B1HSD17B2KCNN4 | |
| SCHEMBL12569583 | 0.84 | CNR1 (0.55) | CNR1CNR2KCNN4LMNAHSD17B10 | |
| SCHEMBL3923273 | 0.83 | CNR2 (0.51) | CNR1CNR2HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL10292299 | 0.82 | CNR1 (0.47) | CNR1CNR2HSD17B1HSD17B2KCNN4 | |
| SCHEMBL17420439 | 0.82 | KCNN4 (0.46) | CNR1CNR2HSD17B1HSD17B2KCNN4 | |
| SCHEMBL1068045 | 0.82 | CNR1 (0.50) | CNR1CNR2KCNN4CYP3A4ALDH1A1 | |
| SCHEMBL3507981 | 0.82 | NPC1 (0.49) | CNR1CNR2KCNN4LMNANPC1 | |
| SCHEMBL7780246 | 0.82 | NPSR1 (0.50) | CNR1CNR2KCNN4ALDH1A1LMNA | |
| SCHEMBL5667027 | 0.82 | CNR1 (0.47) | CNR1CNR2HSD17B1HSD17B2KCNN4 | |
| SCHEMBL31560866 | 0.82 | NPSR1 (0.50) | CNR1CNR2KCNN4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010138901-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS, DERIVATIVES THEREOF, AND RELATED METHODS OF USE | BIOGEN IDEC MA INC (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20080292608-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2008-11-27 | — | — | US | disclosed |
| US-20080292608-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2008-11-27 | — | — | US | disclosed |
| US-20080292608-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2008-11-27 | — | — | US | disclosed |
| EP-1945633-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056497-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
| US-7138411-B2 | Substituted benzopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
| US-6492390-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS. | G.D. SEARLE & CO. | 2002-12-10 | — | — | US | disclosed |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-01-24 | — | — | US | disclosed |
| CN-1329607-A | Substituted benzopyran analogs for the treatment of inflammation | SEARLE & CO (US) | 2002-01-02 | — | — | CN | disclosed |
| EP-1123285-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6271253-B1 | CYCLOOXYGENASE INHIBITORS | G.D. SEARLE & CO. | 2001-08-07 | — | — | US | disclosed |
| US-6077850-A | USEFUL FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS INFLAMMATION AND INFLAMMATION-RELATED DISORDERS | G.D. SEARLE & CO. (US) | 2000-06-20 | — | — | US | disclosed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-5298511-A | Alkanoic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-03-29 | — | — | US | disclosed |
| EP-0540165-A1 | Alkanoic acid derivatives | ZENECA LIMITED (GB) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | PTGS1, IL1R1, PTGES2 | CNR1 45/4885CNR2 55/4885HSD17B1 696/4885 |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | CNR1 804/4885CNR2 1576/4885HSD17B1 76/4885 |
| US-20080292608-A1 | Compounds and Compositions as Ppar Modulators | PPARG, PPARA, PPARD | CNR1 291/4885CNR2 417/4885HSD17B1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.